

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Recent advances and emerging therapies in the... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/7-1207/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/7-1207" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Recent advances and emerging therapies in the non-surgical management of ulcerative colitis" />
    
            <meta name="og:title" content="F1000Research Article: Recent advances and emerging therapies in the non-surgical management of ulcerative colitis.">
            <meta name="og:description" content="Read the latest article version by Jan Wehkamp, Eduard F. Stange, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="16514">
            <meta name="article-id" content="15159">
            <meta name="dc.title" content="Recent advances and emerging therapies in the non-surgical management of ulcerative colitis">
            <meta name="dc.description" content="The so-called &ldquo;biologicals&rdquo; (monoclonal antibodies to various inflammatory targets like tumor necrosis factor or integrins) have revolutionized the treatment of inflammatory bowel diseases. In ulcerative colitis, they have an established role in inducing remission in steroid-refractory disease and, thereafter, maintaining remission with or without azathioprine. Nevertheless, their limitations are also obvious: lack of primary response or loss of response during maintenance as well as various, in part severe, side effects. The latter are less frequent in anti-integrin treatment, but efficacy, especially during induction, is delayed. New antibodies as well as small molecules have also demonstrated clinical efficacy and are soon to be licensed for ulcerative colitis. None of these novel drugs seems to be much more effective overall than the competition, but they provide new options in otherwise refractory patients. This increasing complexity requires new algorithms, but it is still premature to outline each drug&rsquo;s role in future treatment paradigms.">
            <meta name="dc.subject" content="ulcerative colitis, therapy, small molecules, biologicals">
            <meta name="dc.creator" content="Wehkamp, Jan">
            <meta name="dc.creator" content="Stange, Eduard F.">
            <meta name="dc.date" content="2018/08/07">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.15159.1">
            <meta name="dc.source" content="F1000Research 2018 7:1207">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="ulcerative colitis">
            <meta name="prism.keyword" content="therapy">
            <meta name="prism.keyword" content="small molecules">
            <meta name="prism.keyword" content="biologicals">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2018/08/07">
            <meta name="prism.volume" content="7">
            <meta name="prism.number" content="1207">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.15159.1">
            <meta name="prism.url" content="https://f1000research.com/articles/7-1207">
            <meta name="citation_title" content="Recent advances and emerging therapies in the non-surgical management of ulcerative colitis">
            <meta name="citation_abstract" content="The so-called &ldquo;biologicals&rdquo; (monoclonal antibodies to various inflammatory targets like tumor necrosis factor or integrins) have revolutionized the treatment of inflammatory bowel diseases. In ulcerative colitis, they have an established role in inducing remission in steroid-refractory disease and, thereafter, maintaining remission with or without azathioprine. Nevertheless, their limitations are also obvious: lack of primary response or loss of response during maintenance as well as various, in part severe, side effects. The latter are less frequent in anti-integrin treatment, but efficacy, especially during induction, is delayed. New antibodies as well as small molecules have also demonstrated clinical efficacy and are soon to be licensed for ulcerative colitis. None of these novel drugs seems to be much more effective overall than the competition, but they provide new options in otherwise refractory patients. This increasing complexity requires new algorithms, but it is still premature to outline each drug&rsquo;s role in future treatment paradigms.">
            <meta name="citation_description" content="The so-called &ldquo;biologicals&rdquo; (monoclonal antibodies to various inflammatory targets like tumor necrosis factor or integrins) have revolutionized the treatment of inflammatory bowel diseases. In ulcerative colitis, they have an established role in inducing remission in steroid-refractory disease and, thereafter, maintaining remission with or without azathioprine. Nevertheless, their limitations are also obvious: lack of primary response or loss of response during maintenance as well as various, in part severe, side effects. The latter are less frequent in anti-integrin treatment, but efficacy, especially during induction, is delayed. New antibodies as well as small molecules have also demonstrated clinical efficacy and are soon to be licensed for ulcerative colitis. None of these novel drugs seems to be much more effective overall than the competition, but they provide new options in otherwise refractory patients. This increasing complexity requires new algorithms, but it is still premature to outline each drug&rsquo;s role in future treatment paradigms.">
            <meta name="citation_keywords" content="ulcerative colitis, therapy, small molecules, biologicals">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Jan Wehkamp">
            <meta name="citation_author_institution" content="Department of Internal Medicine 1, University of T&uuml;bingen, T&uuml;bingen, Germany">
            <meta name="citation_author" content="Eduard F. Stange">
            <meta name="citation_author_institution" content="Department of Internal Medicine 1, University of T&uuml;bingen, T&uuml;bingen, Germany">
            <meta name="citation_publication_date" content="2018/08/07">
            <meta name="citation_volume" content="7">
            <meta name="citation_publication_number" content="1207">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.15159.1">
            <meta name="citation_firstpage" content="1207">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/7-1207/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/7-1207.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=16514 /> <input type=hidden id=articleId name=articleId value=15159 /> <input type=hidden id=xmlUrl value="/articles/7-1207/v1/xml"/> <input type=hidden id=xmlFileName value="-7-1207-v1.xml"> <input type=hidden id=article_uuid value=a7184d48-b14f-4a14-bb47-040efd40cbfa /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Recent advances and emerging therapies in the non-surgical management of ulcerative colitis"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.15159.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.15159.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/7-1207"
  },
  "headline": "Recent advances and emerging therapies in the non-surgical management of ulcerative colitis",
  "datePublished": "2018-08-07T13:57:20",
  "dateModified": "2018-08-07T13:57:20",
  "author": [
    {
      "@type": "Person",
      "name": "Jan Wehkamp"
    },    {
      "@type": "Person",
      "name": "Eduard F. Stange"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "The so-called &ldquo;biologicals&rdquo; (monoclonal antibodies to various inflammatory targets like tumor necrosis factor or integrins) have revolutionized the treatment of inflammatory bowel diseases. In ulcerative colitis, they have an established role in inducing remission in steroid-refractory disease and, thereafter, maintaining remission with or without azathioprine. Nevertheless, their limitations are also obvious: lack of primary response or loss of response during maintenance as well as various, in part severe, side effects. The latter are less frequent in anti-integrin treatment, but efficacy, especially during induction, is delayed. New antibodies as well as small molecules have also demonstrated clinical efficacy and are soon to be licensed for ulcerative colitis. None of these novel drugs seems to be much more effective overall than the competition, but they provide new options in otherwise refractory patients. This increasing complexity requires new algorithms, but it is still premature to outline each drug&rsquo;s role in future treatment paradigms."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/7-1207",
            "name": "Recent advances and emerging therapies in the non-surgical management..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Recent advances and emerging therapies in the non-surgical management... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=16514 data-id=15159 data-downloads="" data-views="" data-scholar="10.12688/f1000research.15159.1" data-recommended="" data-doi="10.12688/f1000research.15159.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/7-1207/v1/pdf?article_uuid=a7184d48-b14f-4a14-bb47-040efd40cbfa" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-15159-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-15159-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-15159-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Wehkamp J and Stange EF. Recent advances and emerging therapies in the non-surgical management of ulcerative colitis [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):1207 (<a class=new-orange href="https://doi.org/10.12688/f1000research.15159.1" target=_blank>https://doi.org/10.12688/f1000research.15159.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-15159-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=15159 id=track-article-signin-15159 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/15159?target=/articles/7-1207">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=16514 /> <input name=articleId type=hidden value=15159 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Recent advances and emerging therapies in the non-surgical management of ulcerative colitis</h1><span class=other-info> [version 1; peer review: 3 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Jan Wehkamp,&nbsp;</span><span class=""><a href="mailto:eduard.stange@rbk.de" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Eduard F. Stange</span></a><a href="https://orcid.org/0000-0002-6474-7387" target=_blank id=author-orcid-1><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-1><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-6474-7387</div></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Jan Wehkamp,&nbsp;</span><span class=""><a href="mailto:eduard.stange@rbk.de" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Eduard F. Stange</span></a><a href="http://orcid.org/0000-0002-6474-7387" target=_blank id=mauthor-orcid-1><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-1><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-6474-7387</div></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 07 Aug 2018 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.15159.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Department of Internal Medicine 1, University of T&uuml;bingen, T&uuml;bingen, Germany<br/> <p> <div class=margin-bottom> Jan Wehkamp <br/> <span>Roles: </span> Writing  Original Draft Preparation, Writing  Review & Editing </div> <div class=margin-bottom> Eduard F. Stange <br/> <span>Roles: </span> Conceptualization, Data Curation, Formal Analysis, Writing  Original Draft Preparation, Writing  Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=37476-36750></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=37475-36749></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=19134-36751></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> The so-called biologicals (monoclonal antibodies to various inflammatory targets like tumor necrosis factor or integrins) have revolutionized the treatment of inflammatory bowel diseases. In ulcerative colitis, they have an established role in inducing remission in steroid-refractory disease and, thereafter, maintaining remission with or without azathioprine. Nevertheless, their limitations are also obvious: lack of primary response or loss of response during maintenance as well as various, in part severe, side effects. The latter are less frequent in anti-integrin treatment, but efficacy, especially during induction, is delayed. New antibodies as well as small molecules have also demonstrated clinical efficacy and are soon to be licensed for ulcerative colitis. None of these novel drugs seems to be much more effective overall than the competition, but they provide new options in otherwise refractory patients. This increasing complexity requires new algorithms, but it is still premature to outline each drugs role in future treatment paradigms. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> ulcerative colitis, therapy, small molecules, biologicals </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Eduard F. Stange (<a href="mailto:eduard.stange@rbk.de">eduard.stange@rbk.de</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Eduard F. Stange </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> Jan Wehkamp has received lecture fees from Falk, AbbVie, Takeda, MSD, Roche, Ferring, and Shire and consulting fees from MSD, Takeda, Novartis, Shire, AbbVie, and Ardeypharm; he is a board member of Defensin Therapeutics and has received honoraria for clinical trials from Amgen, Novartis, Falk, and AbbVie. Eduard F. Stange has received lecture fees from AbbVie, Dr. Falk Pharma, Ferring, and Takeda and advisory board fees from Merck, Takeda, and Jansen. He has received honoraria for clinical studies from AbbVie, Falk, Takeda, Celgene, Gilead, Amgen, Boehringer, Salix, and Pfizer. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp;  2018 Wehkamp J and Stange EF. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Wehkamp J and Stange EF. Recent advances and emerging therapies in the non-surgical management of ulcerative colitis [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):1207 (<a href="https://doi.org/10.12688/f1000research.15159.1" target=_blank>https://doi.org/10.12688/f1000research.15159.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 07 Aug 2018, <b>7</b>(F1000 Faculty Rev):1207 (<a href="https://doi.org/10.12688/f1000research.15159.1" target=_blank>https://doi.org/10.12688/f1000research.15159.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 07 Aug 2018, <b>7</b>(F1000 Faculty Rev):1207 (<a href="https://doi.org/10.12688/f1000research.15159.1" target=_blank>https://doi.org/10.12688/f1000research.15159.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d3418e153>Introduction</h2><p class="" id=d3418e156>Based on so-called biologicals (biological manufacturing process, so far exclusively monoclonal antibodies), the treatment of ulcerative colitis has advanced significantly in recent years. With the introduction of novel small molecules targeting multiple immune effectors, there is more to come. Nevertheless, although all of these new options are nice to have, a cure for this, at times devastating, disease is not on the horizon. Most drug development efforts currently focus on blocking the inflammatory cascade, which most likely is, at least in part, a secondary rather than a primary event. The initial pathogenic level appears to be the slow invasion of commensal bacteria from the colon lumen into the mucosa, facilitated by a mucus barrier dysfunction<sup><a href="#ref-1">1</a></sup>.</p><p class="" id=d3418e163>Much like in Crohns disease, the immune response in ulcerative colitis is directed against bacterial antigens, leading to a predominantly mucosal inflammation beginning in the rectum and variably migrating orally to the cecum<sup><a href="#ref-2">2</a></sup>. The majority of patients, however, maintain a stable disease extent<sup><a href="#ref-3">3</a></sup>. Major clinical symptoms compromising quality of life are diarrhea, abdominal pain, and bloody stools. In the extreme form, a megacolon may develop, although this has become a rare event. Therapy-refractory courses and inflammation-associated colon dysplasia or cancer still require surgery (colectomy), usually with an ileoanal pouch procedure. Extraintestinal manifestations of arthritis, skin disease (pyoderma or erythema nodosum), or ocular inflammation are frequent. The association of colitis with primary sclerosing cholangitis (PSC) is ominous with respect to colon cancer development.</p><p class="" id=d3418e174>The epidemiology of ulcerative colitis indicates dramatic increases, particularly in industrialized countries like Sweden, where between 1963 and 2005 incidence rose fivefold and prevalence nearly 11-fold to 474/100,000<sup><a href="#ref-4">4</a></sup>. Dramatic rises, for example, in currently industrializing countries of Asia suggest ulcerative colitis is becoming a global disease<sup><a href="#ref-5">5</a></sup>. The mechanism(s) behind this rise are obscure and most likely related to environmental factors, since the contribution of genetic predisposition to ulcerative colitis is minor and not subject to such a rapid change.</p><p class="" id=d3418e185>As a side issue, since most of the novel drugs are quite expensive, the availability of these substances unfortunately will be limited to countries with well-financed health services. In many parts of the world, patients are still treated with standard or locally traditional drugs, if at all.</p><p class="" id=d3418e189>This review will start with the standards but focus on the now-available monoclonal antibodies directed against tumor necrosis factor (TNF) and integrins as well as the new small molecules likely to be approved soon. Also, fecal microbiota transfer will be dealt with briefly as a drastic alternative. Advances by new treatments are compared to what is already available, and critical evaluation should include a benefitrisk ratio. As a matter of fact, for novel developments, this judgement is limited by the much smaller number of treated patients during a shorter time period and before marketing is even restricted to the published clinical trials. Thus, similar to our previous review on Crohns disease<sup><a href="#ref-6">6</a></sup>, it is evident that some opinions are just opinions, necessarily subjective, and, admittedly, personal.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d3418e199>Methods</h2><p class="" id=d3418e202>This concise review is non-exhaustive and non-systematic but based on an ongoing PubMed literature screen with the key words Crohns disease and ulcerative colitis. We have focused on the major phase II and III clinical trials to refer to the best evidence available with respect to efficacy. Adverse events are more difficult to judge from this level because of the limited number of patients; here, post-marketing studies are more reliable. To avoid the soft end point of response (i.e. patients are better but not well), we prefer clinical remission. It should be noted that in some studies on ulcerative colitis (see below) and most corresponding trials in Crohns disease non-responders were excluded in the maintenance phase and just the responders were re-randomized following induction. For the long-term analysis, the responder cohort was reset as 100%, indicating selection bias and skewing data compared to straight-through treatment<sup><a href="#ref-7">7</a></sup>. We have also used the <i>traditional</i> end point of number needed to treat (<i>t</i>NNT, number of patients required to obtain one additional remission by the treatment compared to placebo: 100% / difference between treatment and placebo in %) and compared it to the <i>real life</i> NNT (<i>rl</i>NNT, number of patients to achieve one remission including the placebo effect: 100% / total % of patients in remission following treatment). Thus, the <i>t</i>NNT refers to the benefit of treatment minus placebo and the <i>rl</i>NNT to the overall number of patients required to achieve one remission. In a way, the <i>t</i>NNT is of interest to the physician judging the net effect of a drug but the <i>rl</i>NNT is important to the patient as a measure of his chances to go into remission. It should be noted that the placebo effect is a well-established and integral part of daily practice and the clinical efficacy from the patients perspective is based on a combination of different factors including the isolated drug effect. For most of the drug treatments, both NNTs are given in <a href="#f1">Figure 1</a>. Please note that comparisons should be made with caution because the studies differ manifold with respect to patient population, timing, end points, and other factors<sup><a href="#ref-7">7</a></sup>. Direct head-to-head studies are urgently required but not available.</p><a name=f1 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/16514/273cf9e0-f8c2-417d-9a69-f15e122ce8b6_figure1.gif"><img alt="273cf9e0-f8c2-417d-9a69-f15e122ce8b6_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/16514/273cf9e0-f8c2-417d-9a69-f15e122ce8b6_figure1.gif"></a><div class=caption><h3>Figure 1. Numbers needed to treat (traditional and real life).</h3><p id=d3418e251><b>A</b>. The <i>traditional</i> end point of number needed to treat (<i>t</i>NNT, number of patients required to obtain one additional remission by the treatment compared to placebo: 100% / difference between treatment and placebo in %). <b>B</b>. The <i>real life</i> NNT (<i>rl</i>NNT, number of patients to achieve one remission including the placebo effect: 100% / total % of patients in remission following treatment). Ada, adalimumab Ultra 1 and Ultra 2 trials; Inflix, infliximab ACT1 and ACT2 trials; Madcam, MAdCAM antibody PF-00547659; Tofa, tofacitinib Octave 1 and 2 trials.</p></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d3418e278>Standards</h2><p class="" id=d3418e281>Despite important new developments, the standards still form the basis of our treatment pyramid and the new drugs should be judged against this background of proven effectiveness. These standard therapies including corticosteroids, aminosalicylates, and traditional immunomodulators such as azathioprine and methotrexate as well as calcineurin inhibitors will not be covered in depth. Aminosalicylates and, if necessary, corticosteroids are still the standard treatment during acute relapse. Maintenance usually is covered by aminosalicylates. Steroids are not only ineffective but also associated with significant side effects in long-term treatment.</p><p class="" id=d3418e284>If aminosalicylates fail, the Cochrane systematic review concluded that azathioprine appears to be more effective than placebo for the maintenance of remission in ulcerative colitis<sup><a href="#ref-8">8</a></sup>. Its use in Sweden increased fivefold to 34% from 1976 to 2005 and, in parallel, the colectomy rate decreased<sup><a href="#ref-4">4</a></sup>. Concordantly, compared to intolerant patients, those tolerating thiopurines fared much better with respect to colectomy rate, hospital admissions, progression of disease extent, and necessity for anti-TNF therapy<sup><a href="#ref-9">9</a></sup>. In England, thiopurine exposure for more than 12 months reduced the likelihood of colectomy by a remarkable 71%<sup><a href="#ref-10">10</a></sup>. Although still disputed, some data even indicate protection against dysplasia/colon cancer by aminosalicylates<sup><a href="#ref-11">11</a></sup> and others by thiopurines<sup><a href="#ref-12">12</a></sup>. These positive effects are probably due to unspecific anti-inflammatory activity. However, so far, none of these likely benefits of standard long-term therapy have been conclusively shown for anti-TNFs<sup><a href="#ref-13">13</a></sup> or anti-integrins in ulcerative colitis.</p><p class="" id=d3418e316>The benefit of methotrexate in this disease is disputed, but it may induce steroid-free clinical remission<sup><a href="#ref-14">14</a></sup>. On the other hand, ciclosporin is equivalent to infliximab in steroid-refractory acute severe colitis<sup><a href="#ref-15">15</a></sup>. The other calcineurin inhibitor, tacrolimus, also appears to be effective<sup><a href="#ref-16">16</a></sup> and may be comparable to anti-TNF agents<sup><a href="#ref-17">17</a></sup>, especially in the short term<sup><a href="#ref-18">18</a>,<a href="#ref-19">19</a></sup>. Unfortunately, owing to the lack of appropriate business models for older drugs without the possibility of intellectual property protection, calcineurin inhibitors are not licensed for use in ulcerative colitis in Europe.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d3418e345>Anti-tumor necrosis factor</h2><p class="" id=d3418e348>Two parallel trials (ACT1 and ACT2) proved the efficacy of infliximab, the first anti-TNF antibody, in ulcerative colitis<sup><a href="#ref-20">20</a></sup>. The primary end point of response (not remission) was achieved in 69% and 64%, respectively, at a dose of 5 mg/kg and in only 37 and 29%, respectively, in placebo patients. Response was defined as a drop but not necessarily normalization of the Mayo score of disease activity. Therefore, this is a much softer end point than remission, which was achieved in 39% (ACT1) and 34% (ACT2) compared to 15 and 6% of placebo patients. The resulting <i>t</i>NNT for remission was 4.2 or 3.6 in the two studies, respectively, and the <i>rl</i>NNT was 2.6 or 2.9. All patients randomized initially in ACT1 and ACT2 were continued after induction and followed on the drug. However, the proportion with sustained clinical remission dropped to 20.5% after 54 weeks despite continued treatment, resulting in a <i>t</i>NNT of 7.2 (more than seven patients have to be treated to achieve one additional clinical remission over 54 weeks) and a <i>rl</i>NNT of 4.9 (nearly five patients have to be treated to achieve remission up to week 54). At any rate, in ulcerative colitis, there is a majority of non-remitters at 8 weeks, and four out of five patients fail infliximab therapy after 1 year. Also, there is loss of response in about 30% of patients between 8 and 54 weeks in ACT1.</p><p class="" id=d3418e367>The reasons for this loss of response are unclear, but probably both significant intestinal secretion of the drug and immunological neutralization through anti-idiotypic antibody formation are relevant mechanisms<sup><a href="#ref-21">21</a><a href="#ref-23">23</a></sup>. Particularly with severe inflammation, infliximab appears to be lost from the mucosa, which will likely limit its efficacy. Trough serum levels are a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis<sup><a href="#ref-24">24</a></sup> and dose/interval adaptation based on these levels is often helpful. Predictors of early response are younger age and p-ANCA seronegativity<sup><a href="#ref-25">25</a></sup>.</p><p class="" id=d3418e385>On the other hand, since the patients recruited for the two studies were refractory to their concurrent medication, even this limited efficacy is of significant value to the responding patient. Under real life conditions in a Swedish multicenter study, 49% achieved steroid-free clinical remission after 12 months, indicating that proper selection may help improve outcome<sup><a href="#ref-26">26</a></sup>. Also, cotreatment with azathioprine may play a role, since it is clinically equivalent to infliximab<sup><a href="#ref-27">27</a></sup>, but the combination of both drugs nearly doubles remission rates. Azathioprine but probably not methotrexate may suppress neutralizing antibody formation, and accordingly immunomodulator use is associated with a decreased likelihood of anti-TNF discontinuation<sup><a href="#ref-28">28</a></sup>.</p><p class="" id=d3418e400>The case for adalimumab in ulcerative colitis is much weaker. In two separate studies, drug versus placebo remission rates after 8 weeks were 18.5% versus 10% (Ultra 1) and 16.5% versus 9.3% (Ultra 2), respectively<sup><a href="#ref-29">29</a>,<a href="#ref-30">30</a></sup>. This results in a <i>t</i>NNT of 11.8 and 13.9, respectively, and the corresponding <i>rl</i>NNTs were 5.4 and 6, respectively. The corresponding values for week 52 were 17.3 and 8.5% (placebo), with a <i>t</i>NNT of 12.5 and an <i>rl</i>NNT of 5.8<sup><a href="#ref-30">30</a></sup>. In infliximab-experienced patients included only in Ultra 2, there was no benefit. Similar to infliximab, trough levels of adalimumab are significantly higher in patients who are in clinical remission and in those with mucosal healing<sup><a href="#ref-31">31</a></sup>. However, unlike infliximab, post hoc analysis of six randomized trials in both Crohns disease and ulcerative colitis demonstrated no efficacy benefits with immunomodulator plus adalimumab combination therapy<sup><a href="#ref-32">32</a></sup>.</p><p class="" id=d3418e436>Subcutaneous golimumab, the final anti-TNF in this discussion, also may induce and maintain remission in ulcerative colitis. Remission following induction was achieved in 18 versus 6% (placebo), with a <i>t</i>NNT of 8.8 at week 6 and an <i>rl</i>NNT of 5.6. Maintenance of remission was possible in 23.227.8 at the two doses of 50 and 100 mg, respectively, versus 15.6% (placebo)<sup><a href="#ref-33">33</a>,<a href="#ref-34">34</a></sup>. Notably, these numbers refer only to the induction responders and not the starting population.</p><p class="" id=d3418e452>An interesting comparison using network meta-analysis comparing the different anti-TNFs accordingly reveals superior odds ratios for induction of remission with infliximab (5.1) compared to adalimumab (1.8) and golimumab (3.5) in anti-TNF-nave patients<sup><a href="#ref-35">35</a></sup>. In principle, this is a fair comparison because prior futile treatment with another anti-TNF significantly worsens the outcome. In contrast, infliximab was inferior to adalimumab for maintaining remission but was similar to golimumab.</p><p class="" id=d3418e459>Interestingly, in a cost calculation<sup><a href="#ref-36">36</a></sup>, golimumab provided the lowest cost per additional remission ($935) but infliximab was associated with the largest additional number of estimated remissions, although at higher cost ($1,975 per remission). Adalimumab was the most expensive at $7,430 per remission. Since the biosimilars are cheaper and now available, at least for infliximab and soon for adalimumab, costs will drop somewhat, but expenses are still far beyond the standard therapies discussed briefly above.</p><p class="" id=d3418e466>An unresolved problem is when and how to stop an anti-TNF. Although it should not be a cost problem, discontinuation of an anti-TNF is often requested by patients. The best strategy is unclear, including the continued use of azathioprine or maintenance with an anti-TNF after induction with combination therapy. Taken together in both Crohns disease and ulcerative colitis, the relapse rate upon interruption is about 19% per patient year but 80% responded upon re-introduction<sup><a href="#ref-37">37</a></sup>. In the end, this will always remain an individual decision personalized to the patients prior course.</p><p class="" id=d3418e473>Side effects of anti-TNFs are manifold and beyond the scope of this discussion. However, it is important to realize that the clinical effect comes at a cost, and in the case of anti-TNFs this largely refers to opportunistic infections, including reactivation of latent tuberculosis, which are sometimes serious and require hospitalization<sup><a href="#ref-38">38</a></sup>. An intriguing report from Denmark suggests a much higher risk for serious infections in adalimumab than infliximab users, even fivefold for serious infections requiring hospitalization<sup><a href="#ref-39">39</a></sup>. The risk for malignant melanoma is marginally increased by anti-TNF, and the issue of non-Hodgkin lymphoma is controversial. Similarly, it remains unclear whether the statistically increased risk for postoperative complications is real or due to case selection<sup><a href="#ref-40">40</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d3418e491>Anti-integrin</h2><p class="" id=d3418e494>In contrast to anti-TNFs, which affect inflammatory cells by interacting with membrane-linked TNF and inducing apoptosis, the anti-integrins block mucosal entry by interfering with lymphocyteendothelial cell binding. This leaves already-resident cells in the mucosa intact and may explain the long interval of action: anti-integrins are the azathioprine of the antibodies. Interestingly, recent data actually support the concept that vedolizumab, an anti-integrin with 47 antagonism, has substantial effects on innate immunity, including changes in macrophage populations<sup><a href="#ref-41">41</a></sup>.</p><p class="" id=d3418e501>In contrast to natalizumab, which induced cerebral JC-virus infection (progressive multifocal leukoencephalopathy), vedolizumab as an 47 antagonist is more intestine specific and appears to be safe in this respect. In the Gemini I trial<sup><a href="#ref-42">42</a></sup> following 6 weeks of induction, remission rates amounted to 16.9 versus 5.4% (<i>t</i>NNT=8.7 and <i>rl</i>NNT=5.9). The 47.1% responders were selected to continue and re-randomized, achieving remission after 52 weeks at 41.8% (vedolizumab given every 8 weeks) and 44.8% (given every 4 weeks). If multiplied out, around 21% of the initial starter population might end up in remission, provided that none of the non-responders at week 6 were late remitters. The therapeutic results achieved with vedolizumab following anti-TNF failure were somewhat compromised compared to anti-TNF-nave patients<sup><a href="#ref-43">43</a></sup>. If this is taken into account<sup><a href="#ref-35">35</a></sup>, the odds ratio of 4.4 for achieving remission upon induction is in the range of infliximab (5.1) but for maintenance with its odds ratio of 3.6 is superior to all the anti-TNFs (1.22.0).</p><p class="" id=d3418e522>When used in the real world as an open medication, one-third of patients with prior anti-TNF failure in France achieved steroid-free clinical remission with vedolizumab<sup><a href="#ref-44">44</a></sup>. In Germany, among patients who started vedolizumab for active ulcerative colitis, 25% were in remission at week 54<sup><a href="#ref-45">45</a></sup>. This is quite similar to the remission rates calculated for the starter cohort above. Possibly, the combination of calcineurin inhibitors with vedolizumab may significantly enhance therapeutic action in non or slow responders to the antibody, but experience is limited to small patient series<sup><a href="#ref-46">46</a></sup>. Even less is known about vedolizumab combined with anti-TNF<sup><a href="#ref-47">47</a></sup>.</p><p class="" id=d3418e541>The side effect profile of vedolizumab was reassuring in the controlled trials with some cases of nasopharyngitis or arthralgia. Even in the post-marketing studies, it was inconspicuous<sup><a href="#ref-48">48</a></sup>, also with respect to enteric infections. A possible signal was a hike in post-surgical complications<sup><a href="#ref-49">49</a></sup>, although this was not consistent in other studies. It is probably advisable to establish a drug clearance interval before surgery for anti-TNFs as well as vedolizumab, if clinically feasible.</p><p class="" id=d3418e553>Abrilumab is another antibody directed against the same target, 47, with remission rates in a phase II trial reaching 13.4% compared to 4.4% in the placebo group, but this phase IIb trial is not fully published.</p><p class="" id=d3418e556>Etrolizumab is also a monoclonal antibody directed against a different target, the 7 subunit of 47 and also of E7, which is relevant for epithelial cell cadherinlymphocyte interactions. Thus, this antibody is less intestine specific but also suppresses intraepithelial lymphocyte retention. Phase III trials in ulcerative colitis are ongoing, but the phase II study was at least promising: no patients in the placebo group had clinical remission at week 10 compared with 21% in the 100 mg group (<i>t</i>NNT=4.8 and <i>rl</i>NNT=4.8) and 10% in the 300 mg plus loading dose group<sup><a href="#ref-50">50</a></sup>.</p><p class="" id=d3418e569>Addressing the counterpart of the integrins at the endothelial cell with a MAdCAM antibody, PF-00547659, has also proven effective in a phase II trial<sup><a href="#ref-51">51</a></sup>. Lacking a dose response, the maximal remission rate was 16.7% at 22.5 mg compared to 2.7% in the placebo group (<i>t</i>NNT=7.1 and <i>rl</i>NNT=6).</p><p class="" id=d3418e582>Another interesting development is AJM300, an oral inhibitor of 4 which in an induction trial achieved clinical remission in 23.5% compared to 3.9% in the placebo group<sup><a href="#ref-52">52</a></sup>. These oral drugs will obviate the immunogenicity that all monoclonal antibodies have in common.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d3418e593>Janus kinase inhibitors</h2><p class="" id=d3418e596>In contrast to the monoclonal antibodies discussed above, there is also a recent extension of oral small molecule alternatives. The most promising substances to be marketed for ulcerative colitis are the Janus kinase (JAK) inhibitors, the most advanced being tofacitinib. JAKs are intracellular signal mediators activated upon cytokine binding and interacting with the so-called STATs. There are several JAKs, and the currently developed inhibitors differ with respect to their selectivity<sup><a href="#ref-53">53</a></sup>.</p><p class="" id=d3418e603>Tofacitinib inhibits all JAKs but preferentially JAK1 and JAK3. It is already approved in Europe for use in rheumatoid arthritis and, based on the phase III Octave trials<sup><a href="#ref-54">54</a></sup>, probably will be licensed for use in ulcerative colitis as well. In the Octave Induction 1 trial, remission at 8 weeks occurred in 18.5% with tofacitinib and in 8.2% in the placebo group (<i>t</i>NNT=9.4 and <i>rl</i>NNT=5.4). In the parallel Octave Induction 2 trial, the respective numbers were 16.6 and 3.6% (<i>t</i>NNT=7.7 and <i>rl</i>NNT=6). Responders (59.9 and 55% in Octave 1 and 2, respectively) were entered into the Sustain maintenance phase, and at 52 weeks remission in this subgroup was achieved in 3441% depending on dose. Again, if multiplied out with the proportion of responders, about one in four patients starting the trial maintained remission for 1 year. Adverse event signals were observed with respect to non-melanoma skin cancer, cardiovascular events, increased lipid levels, and infections like herpes zoster. More extensive experience with the rheumatological patients suggests that the overall risk of infections and mortality rates appear to be similar to the biological agents and malignancies occurred in the expected range in these rheumatoid arthritis patients<sup><a href="#ref-55">55</a>,<a href="#ref-56">56</a></sup>.</p><p class="" id=d3418e630>Competitors in the field are upadacitinib (JAK1 inhibitor) with a positive phase II trial in ulcerative colitis and filgotinib, another JAK inhibitor, which has been successful in Crohns disease, but no data for ulcerative colitis are available.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d3418e636>Other small molecules</h2><p class="" id=d3418e639>Ozanimod is an oral antagonist of the sphingosine 1 receptor subtypes 1 and 5 that induces peripheral lymphocyte sequestration, potentially preventing them from infiltrating the gastrointestinal tract. In a controlled phase II trial<sup><a href="#ref-57">57</a></sup>, ozanimod at week 32 increased the remission rate from 6% in the placebo group to 2126% (<i>t</i>NNT=5 and <i>rl</i>NNT=3.8) in the two doses applied. Blood lymphocyte counts declined by 49% from baseline; the most common side effects were anemia, headache, and bradycardia. The results of the phase III trial are awaited.</p><p class="" id=d3418e652>A very different approach was the effort to stabilize the colonic mucus level by administration of modified-release phosphatidylcholine (LT-02). After 12 weeks of treatment, remission was achieved in 15% in the placebo group compared with 31.4% in the highest dose group<sup><a href="#ref-58">58</a></sup>. This phase II trial was followed by an unpublished negative phase III trial, unfortunately.</p><p class="" id=d3418e659>There is more to come including phosphodiesterase inhibitors such as apremilast or topically applied oligonucleotides acting as Toll-like receptor 9 agonists, but larger trials are required for qualified judgement.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d3418e665>Fecal microbiome transfer</h2><p class="" id=d3418e668>A radically different approach, again, is the administration of a heterologous fecal microbiome from healthy donors to ulcerative colitis patients through duodenal/jejunal intubation, colonoscopy, or enemas. A 2,000-year-old hypothesis suggests a modifying role for the microbiomes composition in disease processes. Overall, most but not all controlled trials and a meta-analysis<sup><a href="#ref-59">59</a><a href="#ref-62">62</a></sup> were positive, achieving remission rates significantly above controls, but the remedy is still a black box (maybe brown box is more appropriate). In a remarkable course, a negative trial turned positive when a super-donor returned to the study after pausing because of an illness<sup><a href="#ref-59">59</a></sup>. The vast majority of those patients receiving his feces (rather than from the other donors) experienced benefit, although the peculiarities of his fecal microbiome are still enigmatic. Possibly, antagonizing the reduced diversity in a patients microbiome by increasing bacterial species richness with donor feces may determine clinical success<sup><a href="#ref-63">63</a></sup>. However, quite surprisingly, a sterile fecal filtrate was also effective in pseudomembranous colitis, suggesting that the relevant effector is rather the virome including bacteriophages<sup><a href="#ref-64">64</a></sup>. Accordingly, there is much to be learned before a messy procedure proven to be a cure in many <i>Clostridium difficile</i> relapsers becomes standard in ulcerative colitis.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d3418e696>Outlook: selecting patients, drugs, and end points</h2><p class="" id=d3418e699>It is obvious from this overview that the situation is getting much more complex for both the physician and the patient. Rather than following a straightforward algorithm of (rapid) step up from aminosalicylates to corticosteroids to anti-TNF and azathioprine in order to achieve and maintain (steroid-free) remission, we now have a choice. In a given clinical situation, is anti-TNF appropriate or, because of convincing maintenance and low side effects, is vedolizumab or, in the future, any of the other anti-integrins? Clearly, in severe disease requiring urgent relief, an anti-TNF is more appropriate, but in the longer term loss of response may become a problem. But what about tofacitinib versus azathioprine? Maybe also timing and clinical activity are the key. It is also unclear whether the small molecules now entering the market should generally be used before the monoclonals or in combination with them. Nevertheless, with the current lack of comparative trials, all conclusions have to be indirect and speculative.</p><p class="" id=d3418e702>Moreover, we need a personalized approach because what counts is to have the right choice for the right patient. Unfortunately, there are no reliable tools for the identification of patients at greater risk for a complicated disease course. In addition to the clinical context, molecular approaches to identify likely responders or remitters are currently in focus. At least in Crohns disease, the number of membrane-bound TNF-expressing mucosal inflammatory cells is related to the response rate: with higher numbers 92%, and with lower numbers only 15%<sup><a href="#ref-65">65</a></sup>. Furthermore, expression of the proinflammatory cytokine oncostatin M is negatively related to the outcome of anti-TNF therapy<sup><a href="#ref-66">66</a></sup>. In ulcerative colitis, mucosal 47 levels were associated with favorable clinical development during vedolizumab treatment<sup><a href="#ref-67">67</a></sup>, and the same holds true for E gene expression and etrolizumab<sup><a href="#ref-68">68</a></sup>. Thus, the selection of patients to improve response rates based on molecular preconditions is at least on the horizon, although certainly not yet as a routine procedure.</p><p class="" id=d3418e721>Finally, another relevant issue is the antagonistic discussion about end points where regulatory boards prefer patient-related outcome measures and the pharmaceutical industry (and some experts in the field) rather opt for endoscopic or preferably histological remission. On the one hand, there are significant discrepancies between patient-reported outcomes and endoscopic and histological appearances in ulcerative colitis<sup><a href="#ref-69">69</a></sup>. There is very limited evidence that treatment should necessarily be escalated until deep remission is achieved, although objective remission may be prognostically beneficial. The issue is compounded by lacking agreement of the investigators using endoscopic scores<sup><a href="#ref-70">70</a></sup>, and the placebo rate, even of endoscopic remission, in ulcerative colitis is a remarkable 23%<sup><a href="#ref-71">71</a></sup>. Thus, the use of endoscopy to steer treatment is unsatisfactory. Confocal microscopy may give more solid information but is still not widely available<sup><a href="#ref-72">72</a></sup>. Clearly, as a prognostic factor, histology is superior to clinical or endoscopy criteria<sup><a href="#ref-73">73</a>,<a href="#ref-74">74</a></sup>, but this does not necessarily imply that histology should guide treatment escalation. Even fecal markers like calprotectin were superior to the Mayo endoscopic score in a study from Japan<sup><a href="#ref-75">75</a></sup>. The uncertainties quoted are part of the reason why there is very limited uptake in real-world practice of the treat to target recommendations supported by the pharmaceutical industry and some experts<sup><a href="#ref-76">76</a></sup>.</p><p class="" id=d3418e756>In conclusion, the therapeutic options in ulcerative colitis have grown rapidly and will continue to do so. None of the current or currently developed drugs will cure the disease or even attack the initial pathophysiology. Also, there is no drug available or close to marketing which achieves and maintains remission in the majority of patients. Although it is a significant advance to have more alternatives in otherwise treatment-refractory patients, the globally increasing disease of ulcerative colitis remains without real medical remedy, except for surgery (but this is another discussion).</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d3418e1 class=n-a></a><h2 class=main-title id=d3692>Competing interests</h2><p class=metadata-entry><a name=d3418e90 class=n-a></a><p id=d3418e91> Jan Wehkamp has received lecture fees from Falk, AbbVie, Takeda, MSD, Roche, Ferring, and Shire and consulting fees from MSD, Takeda, Novartis, Shire, AbbVie, and Ardeypharm; he is a board member of Defensin Therapeutics and has received honoraria for clinical trials from Amgen, Novartis, Falk, and AbbVie. Eduard F. Stange has received lecture fees from AbbVie, Dr. Falk Pharma, Ferring, and Takeda and advisory board fees from Merck, Takeda, and Jansen. He has received honoraria for clinical studies from AbbVie, Falk, Takeda, Celgene, Gilead, Amgen, Boehringer, Salix, and Pfizer.</p></p></div><div class=back-section><a name=d3418e1 class=n-a></a><h2 class=main-title id=d3694>Grant information</h2><p>The author(s) declared that no grants were involved in supporting this work.</p></div><div class=back-section><a name=d3418e763 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d3938>References</h2><div class="section ref-list"><a name=d3418e763 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d3418e770 class=n-a></a>Hansson GC: Role of mucus layers in gut infection and inflammation. <i>Curr Opin Microbiol.</i> 2012; <b>15</b>(1): 5762. <a target=xrefwindow id=d3418e778 href="http://www.ncbi.nlm.nih.gov/pubmed/22177113">PubMed Abstract </a> | <a target=xrefwindow id=d3418e781 href="http://dx.doi.org/10.1016/j.mib.2011.11.002">Publisher Full Text </a> | <a target=xrefwindow id=d3418e784 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3716454">Free Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d3418e793 class=n-a></a>Ungaro R, Mehandru S, Allen PB, <i> et al.</i>: Ulcerative colitis. <i>Lancet.</i> 2017; <b>389</b>(10080): 175670. <a target=xrefwindow id=d3418e804 href="http://www.ncbi.nlm.nih.gov/pubmed/27914657">PubMed Abstract </a> | <a target=xrefwindow id=d3418e807 href="http://dx.doi.org/10.1016/S0140-6736(16)32126-2">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d3418e816 class=n-a></a>Safroneeva E, Vavricka S, Fournier N, <i> et al.</i>: Systematic analysis of factors associated with progression and regression of ulcerative colitis in 918 patients. <i>Aliment Pharmacol Ther.</i> 2015; <b>42</b>(5): 5408. <a target=xrefwindow id=d3418e827 href="http://www.ncbi.nlm.nih.gov/pubmed/26148503">PubMed Abstract </a> | <a target=xrefwindow id=d3418e830 href="http://dx.doi.org/10.1111/apt.13307">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/729083544"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3418e839 class=n-a></a>Eriksson C, Cao Y, Rundquist S, <i> et al.</i>: Changes in medical management and colectomy rates: a population-based cohort study on the epidemiology and natural history of ulcerative colitis in rebro, Sweden, 1963-2010. <i>Aliment Pharmacol Ther.</i> 2017; <b>46</b>(8): 74857. <a target=xrefwindow id=d3418e850 href="http://www.ncbi.nlm.nih.gov/pubmed/28833287">PubMed Abstract </a> | <a target=xrefwindow id=d3418e853 href="http://dx.doi.org/10.1111/apt.14268">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/729083544">F1000 Recommendation</a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725717456"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3418e866 class=n-a></a>Molodecky NA, Soon IS, Rabi DM, <i> et al.</i>: Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. <i>Gastroenterology.</i> 2012; <b>142</b>(1): 4654.e42; quiz e30. <a target=xrefwindow id=d3418e877 href="http://www.ncbi.nlm.nih.gov/pubmed/22001864">PubMed Abstract </a> | <a target=xrefwindow id=d3418e880 href="http://dx.doi.org/10.1053/j.gastro.2011.10.001">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725717456">F1000 Recommendation</a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d3418e894 class=n-a></a>Stange EF, Wehkamp J: Recent advances in understanding and managing Crohn's disease [version 1; referees: 4 approved]. <i>F1000Res.</i> 2016; <b>5</b>: 2896. <a target=xrefwindow id=d3418e902 href="http://www.ncbi.nlm.nih.gov/pubmed/28163902">PubMed Abstract </a> | <a target=xrefwindow id=d3418e905 href="http://dx.doi.org/10.12688/f1000research.9890.1">Publisher Full Text </a> | <a target=xrefwindow id=d3418e908 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5271584">Free Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d3418e917 class=n-a></a>Ghosh S, Sandborn WJ, Colombel JF, <i> et al.</i>: Interpreting Registrational Clinical Trials of Biological Therapies in Adults with Inflammatory Bowel Diseases. <i>Inflamm Bowel Dis.</i> 2016; <b>22</b>(11): 271123. <a target=xrefwindow id=d3418e928 href="http://www.ncbi.nlm.nih.gov/pubmed/27585411">PubMed Abstract </a> | <a target=xrefwindow id=d3418e931 href="http://dx.doi.org/10.1097/MIB.0000000000000909">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d3418e940 class=n-a></a>Timmer A, Patton PH, Chande N, <i> et al.</i>: Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. <i>Cochrane Database Syst Rev.</i> 2016; (5): CD000478. <a target=xrefwindow id=d3418e948 href="http://www.ncbi.nlm.nih.gov/pubmed/27192092">PubMed Abstract </a> | <a target=xrefwindow id=d3418e951 href="http://dx.doi.org/10.1002/14651858.CD000478.pub4">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732991248"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3418e960 class=n-a></a>Eriksson C, Rundquist S, Cao Y, <i> et al.</i>: Impact of thiopurines on the natural history and surgical outcome of ulcerative colitis: a cohort study. <i>Gut.</i> 2018. pii: gutjnl-2017-315521. <a target=xrefwindow id=d3418e968 href="http://www.ncbi.nlm.nih.gov/pubmed/29618498">PubMed Abstract </a> | <a target=xrefwindow id=d3418e971 href="http://dx.doi.org/10.1136/gutjnl-2017-315521">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732991248">F1000 Recommendation</a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d3418e984 class=n-a></a>Chhaya V, Saxena S, Cecil E, <i> et al.</i>: The impact of timing and duration of thiopurine treatment on colectomy in ulcerative colitis: a national population-based study of incident cases between 1989-2009. <i>Aliment Pharmacol Ther.</i> 2015; <b>41</b>(1): 8798. <a target=xrefwindow id=d3418e995 href="http://www.ncbi.nlm.nih.gov/pubmed/25382737">PubMed Abstract </a> | <a target=xrefwindow id=d3418e998 href="http://dx.doi.org/10.1111/apt.13017">Publisher Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727127611"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3418e1007 class=n-a></a>Carrat F, Seksik P, Colombel JF, <i> et al.</i>: The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease. <i>Aliment Pharmacol Ther.</i> 2017; <b>45</b>(4): 53341. <a target=xrefwindow id=d3418e1018 href="http://www.ncbi.nlm.nih.gov/pubmed/27995656">PubMed Abstract </a> | <a target=xrefwindow id=d3418e1021 href="http://dx.doi.org/10.1111/apt.13897">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727127611">F1000 Recommendation</a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d3418e1035 class=n-a></a>Gordillo J, Cabr E, Garcia-Planella E, <i> et al.</i>: Thiopurine Therapy Reduces the Incidence of Colorectal Neoplasia in Patients with Ulcerative Colitis. Data from the ENEIDA Registry. <i>J Crohns Colitis.</i> 2015; <b>9</b>(12): 106370. <a target=xrefwindow id=d3418e1046 href="http://www.ncbi.nlm.nih.gov/pubmed/26351379">PubMed Abstract </a> | <a target=xrefwindow id=d3418e1049 href="http://dx.doi.org/10.1093/ecco-jcc/jjv145">Publisher Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733724382"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3418e1058 class=n-a></a>Olivera P, Spinelli A, Gower-Rousseau C, <i> et al.</i>: Surgical rates in the era of biological therapy: up, down or unchanged? <i>Curr Opin Gastroenterol.</i> 2017; <b>33</b>(4): 24653. <a target=xrefwindow id=d3418e1069 href="http://www.ncbi.nlm.nih.gov/pubmed/28463854">PubMed Abstract </a> | <a target=xrefwindow id=d3418e1072 href="http://dx.doi.org/10.1097/MOG.0000000000000361">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733724382">F1000 Recommendation</a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d3418e1085 class=n-a></a>Carbonnel F, Colombel JF, Filippi J, <i> et al.</i>: Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis. <i>Gastroenterology.</i> 2016; <b>150</b>(2): 3808.e4. <a target=xrefwindow id=d3418e1096 href="http://www.ncbi.nlm.nih.gov/pubmed/26632520">PubMed Abstract </a> | <a target=xrefwindow id=d3418e1099 href="http://dx.doi.org/10.1053/j.gastro.2015.10.050">Publisher Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727169771"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3418e1108 class=n-a></a>Laharie D, Bourreille A, Branche J, <i> et al.</i>: Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab. <i>Gut.</i> 2018; <b>67</b>(2): 23743. <a target=xrefwindow id=d3418e1119 href="http://www.ncbi.nlm.nih.gov/pubmed/28053054">PubMed Abstract </a> | <a target=xrefwindow id=d3418e1122 href="http://dx.doi.org/10.1136/gutjnl-2016-313060">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727169771">F1000 Recommendation</a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d3418e1135 class=n-a></a>Schmidt KJ, Mller N, Dignass A, <i> et al.</i>: Long-term Outcomes in Steroid-refractory Ulcerative Colitis Treated with Tacrolimus Alone or in Combination with Purine Analogues. <i>J Crohns Colitis.</i> 2016; <b>10</b>(1): 317. <a target=xrefwindow id=d3418e1146 href="http://www.ncbi.nlm.nih.gov/pubmed/26419459">PubMed Abstract </a> | <a target=xrefwindow id=d3418e1149 href="http://dx.doi.org/10.1093/ecco-jcc/jjv175">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d3418e1158 class=n-a></a>Yamamoto T, Shimoyama T, Umegae S, <i> et al.</i>: Tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis: a retrospective observational study. <i>Aliment Pharmacol Ther.</i> 2016; <b>43</b>(6): 70516. <a target=xrefwindow id=d3418e1169 href="http://www.ncbi.nlm.nih.gov/pubmed/26762838">PubMed Abstract </a> | <a target=xrefwindow id=d3418e1172 href="http://dx.doi.org/10.1111/apt.13531">Publisher Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d3418e1182 class=n-a></a>Endo K, Onodera M, Shiga H, <i> et al.</i>: A Comparison of Short- and Long-Term Therapeutic Outcomes of Infliximab- versus Tacrolimus-Based Strategies for Steroid-Refractory Ulcerative Colitis. <i>Gastroenterol Res Pract.</i> 2016; <b>2016</b>: 3162595. <a target=xrefwindow id=d3418e1193 href="http://www.ncbi.nlm.nih.gov/pubmed/26904108">PubMed Abstract </a> | <a target=xrefwindow id=d3418e1196 href="http://dx.doi.org/10.1155/2016/3162595">Publisher Full Text </a> | <a target=xrefwindow id=d3418e1200 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4745932">Free Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d3418e1209 class=n-a></a>Narula N, Marshall JK, Colombel JF, <i> et al.</i>: Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids. <i>Am J Gastroenterol.</i> 2016; <b>111</b>(4): 47791. <a target=xrefwindow id=d3418e1220 href="http://www.ncbi.nlm.nih.gov/pubmed/26856754">PubMed Abstract </a> | <a target=xrefwindow id=d3418e1223 href="http://dx.doi.org/10.1038/ajg.2016.7">Publisher Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/6001"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3418e1232 class=n-a></a>Rutgeerts P, Sandborn WJ, Feagan BG, <i> et al.</i>: Infliximab for induction and maintenance therapy for ulcerative colitis. <i>N Engl J Med.</i> 2005; <b>353</b>(23): 246276. <a target=xrefwindow id=d3418e1243 href="http://www.ncbi.nlm.nih.gov/pubmed/16339095">PubMed Abstract </a> | <a target=xrefwindow id=d3418e1246 href="http://dx.doi.org/10.1056/NEJMoa050516">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/6001">F1000 Recommendation</a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d3418e1259 class=n-a></a>Brandse JF, van den Brink GR, Wildenberg ME, <i> et al.</i>: Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis. <i>Gastroenterology.</i> 2015; <b>149</b>(2): 3505.e2. <a target=xrefwindow id=d3418e1270 href="http://www.ncbi.nlm.nih.gov/pubmed/25917786">PubMed Abstract </a> | <a target=xrefwindow id=d3418e1273 href="http://dx.doi.org/10.1053/j.gastro.2015.04.016">Publisher Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d3418e1282 class=n-a></a>Adedokun OJ, Sandborn WJ, Feagan BG, <i> et al.</i>: Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. <i>Gastroenterology.</i> 2014; <b>147</b>(6): 12961307.e5. <a target=xrefwindow id=d3418e1293 href="http://www.ncbi.nlm.nih.gov/pubmed/25173754">PubMed Abstract </a> | <a target=xrefwindow id=d3418e1296 href="http://dx.doi.org/10.1053/j.gastro.2014.08.035">Publisher Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d3418e1305 class=n-a></a>Yarur AJ, Jain A, Sussman DA, <i> et al.</i>: The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study. <i>Gut.</i> 2016; <b>65</b>(2): 24955. <a target=xrefwindow id=d3418e1316 href="http://www.ncbi.nlm.nih.gov/pubmed/25670812">PubMed Abstract </a> | <a target=xrefwindow id=d3418e1319 href="http://dx.doi.org/10.1136/gutjnl-2014-308099">Publisher Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d3418e1329 class=n-a></a>Seow CH, Newman A, Irwin SP, <i> et al.</i>: Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. <i>Gut.</i> 2010; <b>59</b>(1): 4954. <a target=xrefwindow id=d3418e1340 href="http://www.ncbi.nlm.nih.gov/pubmed/19651627">PubMed Abstract </a> | <a target=xrefwindow id=d3418e1343 href="http://dx.doi.org/10.1136/gut.2009.183095">Publisher Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d3418e1352 class=n-a></a>Ferrante M, Vermeire S, Katsanos KH, <i> et al.</i>: Predictors of early response to infliximab in patients with ulcerative colitis. <i>Inflamm Bowel Dis.</i> 2007; <b>13</b>(2): 1238. <a target=xrefwindow id=d3418e1363 href="http://www.ncbi.nlm.nih.gov/pubmed/17206703">PubMed Abstract </a> | <a target=xrefwindow id=d3418e1366 href="http://dx.doi.org/10.1002/ibd.20054">Publisher Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727146538"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3418e1375 class=n-a></a>Angelison L, Almer S, Eriksson A, <i> et al.</i>: Long-term outcome of infliximab treatment in chronic active ulcerative colitis: a Swedish multicentre study of 250 patients. <i>Aliment Pharmacol Ther.</i> 2017; <b>45</b>(4): 51932. <a target=xrefwindow id=d3418e1386 href="http://www.ncbi.nlm.nih.gov/pubmed/28025840">PubMed Abstract </a> | <a target=xrefwindow id=d3418e1389 href="http://dx.doi.org/10.1111/apt.13893">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727146538">F1000 Recommendation</a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718277581"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3418e1402 class=n-a></a>Panaccione R, Ghosh S, Middleton S, <i> et al.</i>: Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. <i>Gastroenterology.</i> 2014; <b>146</b>(2): 392400.e3. <a target=xrefwindow id=d3418e1413 href="http://www.ncbi.nlm.nih.gov/pubmed/24512909">PubMed Abstract </a> | <a target=xrefwindow id=d3418e1416 href="http://dx.doi.org/10.1053/j.gastro.2013.10.052">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718277581">F1000 Recommendation</a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727330074"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3418e1429 class=n-a></a>Targownik LE, Tennakoon A, Leung S, <i> et al.</i>: Factors Associated with Discontinuation of Anti-TNF Inhibitors Among Persons with IBD: A Population-Based Analysis. <i>Inflamm Bowel Dis.</i> 2017; <b>23</b>(3): 40920. <a target=xrefwindow id=d3418e1440 href="http://www.ncbi.nlm.nih.gov/pubmed/28221250">PubMed Abstract </a> | <a target=xrefwindow id=d3418e1443 href="http://dx.doi.org/10.1097/MIB.0000000000001025">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727330074">F1000 Recommendation</a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d3418e1456 class=n-a></a>Reinisch W, Sandborn WJ, Hommes DW, <i> et al.</i>: Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. <i>Gut.</i> 2011; <b>60</b>(6): 7807. <a target=xrefwindow id=d3418e1467 href="http://www.ncbi.nlm.nih.gov/pubmed/21209123">PubMed Abstract </a> | <a target=xrefwindow id=d3418e1470 href="http://dx.doi.org/10.1136/gut.2010.221127">Publisher Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717097803"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3418e1480 class=n-a></a>Sandborn WJ, van Assche G, Reinisch W, <i> et al.</i>: Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. <i>Gastroenterology.</i> 2012; <b>142</b>(2): 25765.e1-3. <a target=xrefwindow id=d3418e1491 href="http://www.ncbi.nlm.nih.gov/pubmed/22062358">PubMed Abstract </a> | <a target=xrefwindow id=d3418e1494 href="http://dx.doi.org/10.1053/j.gastro.2011.10.032">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717097803">F1000 Recommendation</a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d3418e1507 class=n-a></a>Roblin X, Marotte H, Rinaudo M, <i> et al.</i>: Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. <i>Clin Gastroenterol Hepatol.</i> 2014; <b>12</b>(1): 8084.e2. <a target=xrefwindow id=d3418e1518 href="http://www.ncbi.nlm.nih.gov/pubmed/23891927">PubMed Abstract </a> | <a target=xrefwindow id=d3418e1521 href="http://dx.doi.org/10.1016/j.cgh.2013.07.010">Publisher Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727018616"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3418e1530 class=n-a></a>Colombel JF, Jharap B, Sandborn WJ, <i> et al.</i>: Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy. <i>Aliment Pharmacol Ther.</i> 2017; <b>45</b>(1): 5062. <a target=xrefwindow id=d3418e1541 href="http://www.ncbi.nlm.nih.gov/pubmed/27883215">PubMed Abstract </a> | <a target=xrefwindow id=d3418e1544 href="http://dx.doi.org/10.1111/apt.13838">Publisher Full Text </a> | <a target=xrefwindow id=d3418e1548 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5157781">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727018616">F1000 Recommendation</a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d3418e1561 class=n-a></a>Sandborn WJ, Feagan BG, Marano C, <i> et al.</i>: Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. <i>Gastroenterology.</i> 2014; <b>146</b>(1): 8595; quiz e14-5. <a target=xrefwindow id=d3418e1572 href="http://www.ncbi.nlm.nih.gov/pubmed/23735746">PubMed Abstract </a> | <a target=xrefwindow id=d3418e1575 href="http://dx.doi.org/10.1053/j.gastro.2013.05.048">Publisher Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718020564"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3418e1584 class=n-a></a>Sandborn WJ, Feagan BG, Marano C, <i> et al.</i>: Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. <i>Gastroenterology.</i> 2014; <b>146</b>(1): 96109.e1. <a target=xrefwindow id=d3418e1595 href="http://www.ncbi.nlm.nih.gov/pubmed/23770005">PubMed Abstract </a> | <a target=xrefwindow id=d3418e1598 href="http://dx.doi.org/10.1053/j.gastro.2013.06.010">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718020564">F1000 Recommendation</a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d3418e1611 class=n-a></a>Vickers AD, Ainsworth C, Mody R, <i> et al.</i>: Systematic Review with Network Meta-Analysis: Comparative Efficacy of Biologics in the Treatment of Moderately to Severely Active Ulcerative Colitis. <i>PLoS One.</i> 2016; <b>11</b>(10): e0165435. <a target=xrefwindow id=d3418e1622 href="http://www.ncbi.nlm.nih.gov/pubmed/27776175">PubMed Abstract </a> | <a target=xrefwindow id=d3418e1625 href="http://dx.doi.org/10.1371/journal.pone.0165435">Publisher Full Text </a> | <a target=xrefwindow id=d3418e1629 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5077077">Free Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d3418e1639 class=n-a></a>Toor K, Druyts E, Jansen JP, <i> et al.</i>: Cost per remission and cost per response with infliximab, adalimumab, and golimumab for the treatment of moderately-to-severely active ulcerative colitis. <i>J Med Econ.</i> 2015; <b>18</b>(6): 43746. <a target=xrefwindow id=d3418e1650 href="http://www.ncbi.nlm.nih.gov/pubmed/25629655">PubMed Abstract </a> | <a target=xrefwindow id=d3418e1653 href="http://dx.doi.org/10.3111/13696998.2015.1012513">Publisher Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727103462"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3418e1662 class=n-a></a>Casanova MJ, Chaparro M, Garca-Snchez V, <i> et al.</i>: Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study. <i>Am J Gastroenterol.</i> 2017; <b>112</b>(1): 12031. <a target=xrefwindow id=d3418e1673 href="http://www.ncbi.nlm.nih.gov/pubmed/27958281">PubMed Abstract </a> | <a target=xrefwindow id=d3418e1676 href="http://dx.doi.org/10.1038/ajg.2016.569">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727103462">F1000 Recommendation</a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d3418e1689 class=n-a></a>Targownik LE, Bernstein CN: Infectious and malignant complications of TNF inhibitor therapy in IBD. <i>Am J Gastroenterol.</i> 2013; <b>108</b>(12): 183542, quiz 1843. <a target=xrefwindow id=d3418e1697 href="http://www.ncbi.nlm.nih.gov/pubmed/24042192">PubMed Abstract </a> | <a target=xrefwindow id=d3418e1700 href="http://dx.doi.org/10.1038/ajg.2013.294">Publisher Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727066115"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3418e1709 class=n-a></a>Singh S, Andersen NN, Andersson M, <i> et al.</i>: Comparison of Infliximab and Adalimumab in Biologic-Naive Patients With Ulcerative Colitis: A Nationwide Danish Cohort Study. <i>Clin Gastroenterol Hepatol.</i> 2017; <b>15</b>(8): 12181225.e7. <a target=xrefwindow id=d3418e1720 href="http://www.ncbi.nlm.nih.gov/pubmed/27913244">PubMed Abstract </a> | <a target=xrefwindow id=d3418e1723 href="http://dx.doi.org/10.1016/j.cgh.2016.11.024">Publisher Full Text </a> | <a target=xrefwindow id=d3418e1727 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5447492">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727066115">F1000 Recommendation</a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718000278"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3418e1740 class=n-a></a>Narula N, Charleton D, Marshall JK: Meta-analysis: peri-operative anti-TNF treatment and post-operative complications in patients with inflammatory bowel disease. <i>Aliment Pharmacol Ther.</i> 2013; <b>37</b>(11): 105764. <a target=xrefwindow id=d3418e1748 href="http://www.ncbi.nlm.nih.gov/pubmed/23581515">PubMed Abstract </a> | <a target=xrefwindow id=d3418e1751 href="http://dx.doi.org/10.1111/apt.12313">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718000278">F1000 Recommendation</a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733179087"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3418e1764 class=n-a></a>Zeissig S, Rosati E, Dowds CM, <i> et al.</i>: Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease. <i>Gut.</i> 2018; pii: gutjnl-2018-316023. <a target=xrefwindow id=d3418e1772 href="http://www.ncbi.nlm.nih.gov/pubmed/29730603">PubMed Abstract </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733179087">F1000 Recommendation</a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718083273"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3418e1786 class=n-a></a>Feagan BG, Rutgeerts P, Sands BE, <i> et al.</i>: Vedolizumab as induction and maintenance therapy for ulcerative colitis. <i>N Engl J Med.</i> 2013; <b>369</b>(8): 699710. <a target=xrefwindow id=d3418e1797 href="http://www.ncbi.nlm.nih.gov/pubmed/23964932">PubMed Abstract </a> | <a target=xrefwindow id=d3418e1800 href="http://dx.doi.org/10.1056/NEJMoa1215734">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718083273">F1000 Recommendation</a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726749172"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3418e1813 class=n-a></a>Feagan BG, Rubin DT, Danese S, <i> et al.</i>: Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists. <i>Clin Gastroenterol Hepatol.</i> 2017; <b>15</b>(2): 229239.e5. <a target=xrefwindow id=d3418e1824 href="http://www.ncbi.nlm.nih.gov/pubmed/27639327">PubMed Abstract </a> | <a target=xrefwindow id=d3418e1827 href="http://dx.doi.org/10.1016/j.cgh.2016.08.044">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726749172">F1000 Recommendation</a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d3418e1840 class=n-a></a>Amiot A, Grimaud JC, Peyrin-Biroulet L, <i> et al.</i>: Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease. <i>Clin Gastroenterol Hepatol.</i> 2016; <b>14</b>(11): 15931601.e2. <a target=xrefwindow id=d3418e1851 href="http://www.ncbi.nlm.nih.gov/pubmed/26917043">PubMed Abstract </a> | <a target=xrefwindow id=d3418e1854 href="http://dx.doi.org/10.1016/j.cgh.2016.02.016">Publisher Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d3418e1863 class=n-a></a>Stallmach A, Langbein C, Atreya R, <i> et al.</i>: Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study. <i>Aliment Pharmacol Ther.</i> 2016; <b>44</b>(1112): 1199212. <a target=xrefwindow id=d3418e1874 href="http://www.ncbi.nlm.nih.gov/pubmed/27714831">PubMed Abstract </a> | <a target=xrefwindow id=d3418e1877 href="http://dx.doi.org/10.1111/apt.13813">Publisher Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733218415"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3418e1886 class=n-a></a>Christensen B, Gibson P, Micic D, <i> et al.</i>: Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease. <i>Clin Gastroenterol Hepatol.</i> 2018; pii: S1542-3565(18)30466-X. <a target=xrefwindow id=d3418e1894 href="http://www.ncbi.nlm.nih.gov/pubmed/29751166">PubMed Abstract </a> | <a target=xrefwindow id=d3418e1897 href="http://dx.doi.org/10.1016/j.cgh.2018.04.060">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733218415">F1000 Recommendation</a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733724414"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3418e1910 class=n-a></a>Fischer S, Rath T, Geppert CI, <i> et al.</i>: Long-term Combination Therapy with Anti-TNF plus Vedolizumab Induces and Maintains Remission in Therapy-refractory Ulcerative Colitis. <i>Am J Gastroenterol.</i> 2017; <b>112</b>(10): 16213. <a target=xrefwindow id=d3418e1921 href="http://www.ncbi.nlm.nih.gov/pubmed/28978957">PubMed Abstract </a> | <a target=xrefwindow id=d3418e1924 href="http://dx.doi.org/10.1038/ajg.2017.242">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733724414">F1000 Recommendation</a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727559442"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3418e1938 class=n-a></a>Bye WA, Jairath V, Travis SPL: Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease. <i>Aliment Pharmacol Ther.</i> 2017; <b>46</b>(1): 315. <a target=xrefwindow id=d3418e1946 href="http://www.ncbi.nlm.nih.gov/pubmed/28449273">PubMed Abstract </a> | <a target=xrefwindow id=d3418e1949 href="http://dx.doi.org/10.1111/apt.14075">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727559442">F1000 Recommendation</a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732806988"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3418e1962 class=n-a></a>Lightner AL, Mathis KL, Tse CS, <i> et al.</i>: Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Major Abdominal Operations for Inflammatory Bowel Disease: Retrospective Multicenter Cohort Study. <i>Inflamm Bowel Dis.</i> 2018; <b>24</b>(4): 8716. <a target=xrefwindow id=d3418e1973 href="http://www.ncbi.nlm.nih.gov/pubmed/29509927">PubMed Abstract </a> | <a target=xrefwindow id=d3418e1976 href="http://dx.doi.org/10.1093/ibd/izx076">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732806988">F1000 Recommendation</a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d3418e1989 class=n-a></a>Vermeire S, O'Byrne S, Keir M, <i> et al.</i>: Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. <i>Lancet.</i> 2014; <b>384</b>(9940): 30918. <a target=xrefwindow id=d3418e2000 href="http://www.ncbi.nlm.nih.gov/pubmed/24814090">PubMed Abstract </a> | <a target=xrefwindow id=d3418e2003 href="http://dx.doi.org/10.1016/S0140-6736(14)60661-9">Publisher Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727630964"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3418e2012 class=n-a></a>Vermeire S, Sandborn WJ, Danese S, <i> et al.</i>: Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial. <i>Lancet.</i> 2017; <b>390</b>(10090): 13544. <a target=xrefwindow id=d3418e2023 href="http://www.ncbi.nlm.nih.gov/pubmed/28527704">PubMed Abstract </a> | <a target=xrefwindow id=d3418e2026 href="http://dx.doi.org/10.1016/S0140-6736(17)30930-3">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727630964">F1000 Recommendation</a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d3418e2039 class=n-a></a>Yoshimura N, Watanabe M, Motoya S, <i> et al.</i>: Safety and Efficacy of AJM300, an Oral Antagonist of 4 Integrin, in Induction Therapy for Patients With Active Ulcerative Colitis. <i>Gastroenterology.</i> 2015; <b>149</b>(7): 17751783.e2. <a target=xrefwindow id=d3418e2050 href="http://www.ncbi.nlm.nih.gov/pubmed/26327130">PubMed Abstract </a> | <a target=xrefwindow id=d3418e2053 href="http://dx.doi.org/10.1053/j.gastro.2015.08.044">Publisher Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d3418e2062 class=n-a></a>Olivera P, Danese S, Peyrin-Biroulet L: Next generation of small molecules in inflammatory bowel disease. <i>Gut.</i> 2017; <b>66</b>(2): 199209. <a target=xrefwindow id=d3418e2070 href="http://www.ncbi.nlm.nih.gov/pubmed/27856614">PubMed Abstract </a> | <a target=xrefwindow id=d3418e2073 href="http://dx.doi.org/10.1136/gutjnl-2016-312912">Publisher Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727577400"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3418e2083 class=n-a></a>Sandborn WJ, Su C, Sands BE, <i> et al.</i>: Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. <i>N Engl J Med.</i> 2017; <b>376</b>(18): 172336. <a target=xrefwindow id=d3418e2094 href="http://www.ncbi.nlm.nih.gov/pubmed/28467869">PubMed Abstract </a> | <a target=xrefwindow id=d3418e2097 href="http://dx.doi.org/10.1056/NEJMoa1606910">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727577400">F1000 Recommendation</a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d3418e2110 class=n-a></a>Cohen S, Radominski SC, Gomez-Reino JJ, <i> et al.</i>: Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. <i>Arthritis Rheumatol.</i> 2014; <b>66</b>(11): 292437. <a target=xrefwindow id=d3418e2121 href="http://www.ncbi.nlm.nih.gov/pubmed/25047021">PubMed Abstract </a> | <a target=xrefwindow id=d3418e2124 href="http://dx.doi.org/10.1002/art.38779">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d3418e2133 class=n-a></a>Curtis JR, Lee EB, Kaplan IV, <i> et al.</i>: Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme. <i>Ann Rheum Dis.</i> 2016; <b>75</b>(5): 83141. <a target=xrefwindow id=d3418e2144 href="http://www.ncbi.nlm.nih.gov/pubmed/25902789">PubMed Abstract </a> | <a target=xrefwindow id=d3418e2147 href="http://dx.doi.org/10.1136/annrheumdis-2014-205847">Publisher Full Text </a> | <a target=xrefwindow id=d3418e2151 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4853586">Free Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d3418e2160 class=n-a></a>Sandborn WJ, Feagan BG, Wolf DC, <i> et al.</i>: Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis. <i>N Engl J Med.</i> 2016; <b>374</b>(18): 175462. <a target=xrefwindow id=d3418e2171 href="http://www.ncbi.nlm.nih.gov/pubmed/27144850">PubMed Abstract </a> | <a target=xrefwindow id=d3418e2174 href="http://dx.doi.org/10.1056/NEJMoa1513248">Publisher Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718375655"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3418e2183 class=n-a></a>Karner M, Kocjan A, Stein J, <i> et al.</i>: First multicenter study of modified release phosphatidylcholine "LT-02" in ulcerative colitis: a randomized, placebo-controlled trial in mesalazine-refractory courses. <i>Am J Gastroenterol.</i> 2014; <b>109</b>(7): 104151. <a target=xrefwindow id=d3418e2194 href="http://www.ncbi.nlm.nih.gov/pubmed/24796768">PubMed Abstract </a> | <a target=xrefwindow id=d3418e2197 href="http://dx.doi.org/10.1038/ajg.2014.104">Publisher Full Text </a> | <a target=xrefwindow id=d3418e2201 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4085478">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718375655">F1000 Recommendation</a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d3418e2214 class=n-a></a>Moayyedi P, Surette MG, Kim PT, <i> et al.</i>: Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. <i>Gastroenterology.</i> 2015; <b>149</b>(1): 102109.e6. <a target=xrefwindow id=d3418e2225 href="http://www.ncbi.nlm.nih.gov/pubmed/25857665">PubMed Abstract </a> | <a target=xrefwindow id=d3418e2228 href="http://dx.doi.org/10.1053/j.gastro.2015.04.001">Publisher Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d3418e2238 class=n-a></a>Rossen NG, Fuentes S, van der Spek MJ, <i> et al.</i>: Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis. <i>Gastroenterology.</i> 2015; <b>149</b>(1): 110118.e4. <a target=xrefwindow id=d3418e2249 href="http://www.ncbi.nlm.nih.gov/pubmed/25836986">PubMed Abstract </a> | <a target=xrefwindow id=d3418e2252 href="http://dx.doi.org/10.1053/j.gastro.2015.03.045">Publisher Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727323892"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3418e2261 class=n-a></a>Paramsothy S, Kamm MA, Kaakoush NO, <i> et al.</i>: Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. <i>Lancet.</i> 2017; <b>389</b>(10075): 121828. <a target=xrefwindow id=d3418e2272 href="http://www.ncbi.nlm.nih.gov/pubmed/28214091">PubMed Abstract </a> | <a target=xrefwindow id=d3418e2275 href="http://dx.doi.org/10.1016/S0140-6736(17)30182-4">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727323892">F1000 Recommendation</a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727601321"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3418e2288 class=n-a></a>Paramsothy S, Paramsothy R, Rubin DT, <i> et al.</i>: Faecal Microbiota Transplantation for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. <i>J Crohns Colitis.</i> 2017; <b>11</b>(10): 118099. <a target=xrefwindow id=d3418e2299 href="http://www.ncbi.nlm.nih.gov/pubmed/28486648">PubMed Abstract </a> | <a target=xrefwindow id=d3418e2302 href="http://dx.doi.org/10.1093/ecco-jcc/jjx063">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727601321">F1000 Recommendation</a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d3418e2315 class=n-a></a>Vermeire S, Joossens M, Verbeke K, <i> et al.</i>: Donor Species Richness Determines Faecal Microbiota Transplantation Success in Inflammatory Bowel Disease. <i>J Crohns Colitis.</i> 2016; <b>10</b>(4): 38794. <a target=xrefwindow id=d3418e2326 href="http://www.ncbi.nlm.nih.gov/pubmed/26519463">PubMed Abstract </a> | <a target=xrefwindow id=d3418e2329 href="http://dx.doi.org/10.1093/ecco-jcc/jjv203">Publisher Full Text </a> | <a target=xrefwindow id=d3418e2333 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4946755">Free Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727002783"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3418e2342 class=n-a></a>Ott SJ, Waetzig GH, Rehman A, <i> et al.</i>: Efficacy of Sterile Fecal Filtrate Transfer for Treating Patients With <i>Clostridium difficile</i> Infection. <i>Gastroenterology.</i> 2017; <b>152</b>(4): 799811.e7. <a target=xrefwindow id=d3418e2356 href="http://www.ncbi.nlm.nih.gov/pubmed/27866880">PubMed Abstract </a> | <a target=xrefwindow id=d3418e2360 href="http://dx.doi.org/10.1053/j.gastro.2016.11.010">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727002783">F1000 Recommendation</a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d3418e2373 class=n-a></a>Atreya R, Neumann H, Neufert C, <i> et al.</i>: <i>In vivo</i> imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease. <i>Nat Med.</i> 2014; <b>20</b>(3): 3138. <a target=xrefwindow id=d3418e2387 href="http://www.ncbi.nlm.nih.gov/pubmed/24562382">PubMed Abstract </a> | <a target=xrefwindow id=d3418e2391 href="http://dx.doi.org/10.1038/nm.3462">Publisher Full Text </a> | <a target=xrefwindow id=d3418e2394 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4479137">Free Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727471255"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3418e2404 class=n-a></a>West NR, Hegazy AN, Owens BMJ, <i> et al.</i>: Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. <i>Nat Med.</i> 2017; <b>23</b>(5): 57989. <a target=xrefwindow id=d3418e2415 href="http://www.ncbi.nlm.nih.gov/pubmed/28368383">PubMed Abstract </a> | <a target=xrefwindow id=d3418e2418 href="http://dx.doi.org/10.1038/nm.4307">Publisher Full Text </a> | <a target=xrefwindow id=d3418e2422 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5420447">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727471255">F1000 Recommendation</a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727819745"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3418e2435 class=n-a></a>Fuchs F, Schillinger D, Atreya R, <i> et al.</i>: Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles. <i>Front Immunol.</i> 2017; <b>8</b>: 764. <a target=xrefwindow id=d3418e2446 href="http://www.ncbi.nlm.nih.gov/pubmed/28717358">PubMed Abstract </a> | <a target=xrefwindow id=d3418e2449 href="http://dx.doi.org/10.3389/fimmu.2017.00764">Publisher Full Text </a> | <a target=xrefwindow id=d3418e2453 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5495081">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727819745">F1000 Recommendation</a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d3418e2466 class=n-a></a>Tew GW, Hackney JA, Gibbons D, <i> et al.</i>: Association Between Response to Etrolizumab and Expression of Integrin E and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis. <i>Gastroenterology.</i> 2016; <b>150</b>(2): 47787.e9. <a target=xrefwindow id=d3418e2477 href="http://www.ncbi.nlm.nih.gov/pubmed/26522261">PubMed Abstract </a> | <a target=xrefwindow id=d3418e2480 href="http://dx.doi.org/10.1053/j.gastro.2015.10.041">Publisher Full Text </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726708851"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3418e2489 class=n-a></a>Colombel JF, Keir ME, Scherl A, <i> et al.</i>: Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UC. <i>Gut.</i> 2017; <b>66</b>(12): 20638. <a target=xrefwindow id=d3418e2500 href="http://www.ncbi.nlm.nih.gov/pubmed/27590995">PubMed Abstract </a> | <a target=xrefwindow id=d3418e2503 href="http://dx.doi.org/10.1136/gutjnl-2016-312307">Publisher Full Text </a> | <a target=xrefwindow id=d3418e2507 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5749342">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726708851">F1000 Recommendation</a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732543351"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3418e2520 class=n-a></a>Fernandes SR, Pinto JSLD, Marques da Costa P, <i> et al.</i>: Disagreement Among Gastroenterologists Using the Mayo and Rutgeerts Endoscopic Scores. <i>Inflamm Bowel Dis.</i> 2018; <b>24</b>(2): 25460. <a target=xrefwindow id=d3418e2531 href="http://www.ncbi.nlm.nih.gov/pubmed/29361106">PubMed Abstract </a> | <a target=xrefwindow id=d3418e2534 href="http://dx.doi.org/10.1093/ibd/izx066">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732543351">F1000 Recommendation</a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733114467"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3418e2547 class=n-a></a>Ma C, Guizzetti L, Panaccione R, <i> et al.</i>: Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis. <i>Aliment Pharmacol Ther.</i> 2018; <b>47</b>(12): 157896. <a target=xrefwindow id=d3418e2558 href="http://www.ncbi.nlm.nih.gov/pubmed/29696670">PubMed Abstract </a> | <a target=xrefwindow id=d3418e2561 href="http://dx.doi.org/10.1111/apt.14672">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733114467">F1000 Recommendation</a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732342724"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3418e2575 class=n-a></a>Hundorfean G, Chiriac MT, Mihai S, <i> et al.</i>: Development and Validation of a Confocal Laser Endomicroscopy-Based Score for <i>In Vivo</i> Assessment of Mucosal Healing in Ulcerative Colitis Patients. <i>Inflamm Bowel Dis.</i> 2017; <b>24</b>(1): 3544. <a target=xrefwindow id=d3418e2589 href="http://www.ncbi.nlm.nih.gov/pubmed/29272480">PubMed Abstract </a> | <a target=xrefwindow id=d3418e2593 href="http://dx.doi.org/10.1093/ibd/izx012">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732342724">F1000 Recommendation</a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d3418e2606 class=n-a></a>Park S, Abdi T, Gentry M, <i> et al.</i>: Histological Disease Activity as a Predictor of Clinical Relapse Among Patients With Ulcerative Colitis: Systematic Review and Meta-Analysis. <i>Am J Gastroenterol.</i> 2016; <b>111</b>(12): 1692701. <a target=xrefwindow id=d3418e2617 href="http://www.ncbi.nlm.nih.gov/pubmed/27725645">PubMed Abstract </a> | <a target=xrefwindow id=d3418e2620 href="http://dx.doi.org/10.1038/ajg.2016.418">Publisher Full Text </a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/731933089"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3418e2629 class=n-a></a>Ponte A, Pinho R, Fernandes S, <i> et al.</i>: Impact of Histological and Endoscopic Remissions on Clinical Recurrence and Recurrence-free Time in Ulcerative Colitis. <i>Inflamm Bowel Dis.</i> 2017; <b>23</b>(12): 223844. <a target=xrefwindow id=d3418e2640 href="http://www.ncbi.nlm.nih.gov/pubmed/28991857">PubMed Abstract </a> | <a target=xrefwindow id=d3418e2643 href="http://dx.doi.org/10.1097/MIB.0000000000001275">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/731933089">F1000 Recommendation</a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732783970"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3418e2656 class=n-a></a>Yamamoto T, Shimoyama T, Umegae S, <i> et al.</i>: Endoscopic score vs. fecal biomarkers for predicting relapse in patients with ulcerative colitis after clinical remission and mucosal healing. <i>Clin Transl Gastroenterol.</i> 2018; <b>9</b>(3): 136. <a target=xrefwindow id=d3418e2667 href="http://www.ncbi.nlm.nih.gov/pubmed/29491393">PubMed Abstract </a> | <a target=xrefwindow id=d3418e2670 href="http://dx.doi.org/10.1038/s41424-018-0006-7">Publisher Full Text </a> | <a target=xrefwindow id=d3418e2674 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5862153">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732783970">F1000 Recommendation</a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/728641392"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d3418e2687 class=n-a></a>Bryant RV, Costello SP, Schoeman S, <i> et al.</i>: Limited uptake of ulcerative colitis "treat-to-target" recommendations in real-world practice. <i>J Gastroenterol Hepatol.</i> 2018; <b>33</b>(3): 599607. <a target=xrefwindow id=d3418e2698 href="http://www.ncbi.nlm.nih.gov/pubmed/28806471">PubMed Abstract </a> | <a target=xrefwindow id=d3418e2701 href="http://dx.doi.org/10.1111/jgh.13923">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/728641392">F1000 Recommendation</a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 07 Aug 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-1207&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-1207&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Department of Internal Medicine 1, University of T&uuml;bingen, T&uuml;bingen, Germany<br/> <p> <div class=margin-bottom> Jan Wehkamp <br/> <span>Roles: </span> Writing  Original Draft Preparation, Writing  Review & Editing </div> <div class=margin-bottom> Eduard F. Stange <br/> <span>Roles: </span> Conceptualization, Data Curation, Formal Analysis, Writing  Original Draft Preparation, Writing  Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/7-1207/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 07 Aug 2018, 7:1207 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.15159.1">https://doi.org/10.12688/f1000research.15159.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden">  2018 Wehkamp J and Stange EF. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=16514 data-id=15159 data-downloads="" data-views="" data-scholar="10.12688/f1000research.15159.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/7-1207/v1/pdf?article_uuid=a7184d48-b14f-4a14-bb47-040efd40cbfa" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.15159.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Wehkamp J and Stange EF. Recent advances and emerging therapies in the non-surgical management of ulcerative colitis [version 1; peer review: 3 approved] <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):1207 (<a href="https://doi.org/10.12688/f1000research.15159.1" target=_blank>https://doi.org/10.12688/f1000research.15159.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=15159 id=mobile-track-article-signin-15159 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/15159?target=/articles/7-1207"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=16514 /> <input name=articleId type=hidden value=15159 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Philippe Marteau</strong>, Departments of Hepatology, Gastroenterology and Nutrition, AP-HP, Hpital Saint Antoine, France </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Alan Moss</strong>, Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center, Harvard Medical School , USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> Consultant for Janssen, Gilead, Seres Therapeutics, Boehringer Ingelheim, Theravance. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Tom &Oslash;resland</strong>, Akershus University Hospital, University of Oslo, Norway </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 07 Aug 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-1207&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-1207&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=37476-36750></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=37475-36749></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=19134-36751></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=3><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> <th class="c-report-timeline__headings-version p-article__color--dark">3</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/7-1207/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>07 Aug 18</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Philippe Marteau</strong>, Departments of Hepatology, Gastroenterology and Nutrition, AP-HP, Hpital Saint Antoine, France </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Alan Moss</strong>, Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center, Harvard Medical School , USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> Consultant for Janssen, Gilead, Seres Therapeutics, Boehringer Ingelheim, Theravance. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Tom &Oslash;resland</strong>, Akershus University Hospital, University of Oslo, Norway </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/7-1207&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/7-1207/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Recent advances and emerging therapies in...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/7-1207/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/7-1207/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/7-1207/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Wehkamp J and Stange EF');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/7-1207/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/7-1207",
            templates : {
                twitter : "Recent advances and emerging therapies in the non-surgical management.... Wehkamp J and Stange EF, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/7-1207/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Recent advances and emerging therapies in the non-surgical management of ulcerative colitis", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Recent advances and emerging therapies in the non-surgical management of ulcerative colitis", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/15159/16514")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "16514");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "36749": 0,
                           "36750": 0,
                           "36751": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "61a31fa8-b6bb-4507-808b-47ac40261f40";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-1207.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-1207.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-1207.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/7-1207.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/7-1207.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>